A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium-223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment.

In this study researcher want to gain more information on how the study drug (radium-223) is distributed in the bone, particularly in the tumor free bone in participants with prostate cancer. The study plans to enroll 60 patients with the age of at least 18 years and suffering from prostate cancer which has spread to the bones. Researcher will divide the study participants into 2 groups. Patients in Group 1 should have up to 6 bone metastases and patients for group 2 should have more than 6 bone metastases. The study medication will be given as injection into a vein every 4 weeks up to a maximum of 6 times. To study how radium distributes in the body and particularly in the bones, participants will undergo after study medication intake MRI or CT Scans (imaging techniques).

Study Overview

• Status: Completed
• Conditions: Bone Metastatic Castration-resistant Prostate Cancer
• Intervention / Treatment: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

• Study Type: Interventional
• Enrollment (Actual): 46
• Phase: Phase 1

Contacts and Locations

Study Locations

• Austria
  • Salzburg, Austria, 5020
    • Uniklinikum Salzburg - Landeskrankenhaus
• France
  • Montpellier, France, 34298
    • ICM - Institut du Cancer de Montpellier - Val d'Aurelle
  • Pierre-Bénite, France, 69495
    • HCL - Centre Hospitalier Lyon Sud
  • Saint-Herblain, France, 44800
    • Institut de Cancerologie Ouest - Saint-Herblain
  • Toulouse, France, 31059
    • Institut Claudius Regaud - IUCT Oncopole
• Israel
  • Haifa, Israel, 3109601
    • Rambam Health Corporation
• Italy
  • Emilia-Romagna
    • Reggio Emilia, Emilia-Romagna, Italy, 42123
      • Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale
• Lithuania
  • Vilnius, Lithuania, LT-08660
    • National Cancer Institute
  • Vilnius, Lithuania, LT-08661
    • Vilnius University hospital Santaros klinikos
• United Kingdom
  • London, United Kingdom, NW1 2PG
    • University College London Hospitals Nhs Foundation Trust
  • London, United Kingdom, SE1 7EH
    • Guy's and St. Thomas' NHS Trust, St. Thomas' Hospital
  • Surrey
    • Sutton, Surrey, United Kingdom, SM2 5PT
      • Royal Marsden NHS Trust (Surrey)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants who have histologically confirmed adenocarcinoma of the prostate.
• Participants with bone metastatic CRPC, progressing after 1 or 2 prior lines of systemic treatment for metastatic prostate cancer (including prior treatment for metastatic hormone sensitive prostate mHSPC or metastatic castration resistant prostate cancer mCRPC).
• Participants with at least 2 bone metastases on Tc 99m phosphonate whole body planar bone scans at Screening.
• Documented progression of mCRPC. Disease progression is defined by at least one of the following criteria: a. PCWG3 criteria (defined as 2 consecutive increases in PSA over a previous reference value measured at least one week prior, with a minimal start value of 1.0 ng/mL) or b. ≥2 new bone lesions (according to PCWG3 bone scan criteria) or c. Radiological progression according to RECIST, version 1.1.
• Ability to participate in the required study procedures including all scanning procedures and ability to control pain to ensure tolerance and completion of the necessary scanning procedures.
• Maintenance of medical castration or surgical castration with testosterone less than 50 ng/dL (1.7 nmol/L). If the participant is being treated with luteinizing hormone releasing hormone (LHRH) agonists or antagonists (participant who has not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to start of Screening and must be continued throughout the study.
• Participants must be on a bone health agent prior to the first dose of radium-223 dichloride. Participants with at least 6 months of prior bone health agent (BHA) treatment are preferred.
• Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
• Life expectancy ≥6 months.

Exclusion Criteria:

• Any chronic medical condition requiring continuous systemic corticosteroid treatment at a higher dose than 5 mg prednisone / prednisolone twice daily.
• Pathological finding consistent with neuroendocrine features small cell carcinoma of the prostate.
• Metastatic bone deposits extend of disease (EOD) grades 0 or 4 (according to centrally assessed Tc 99m phosphonate planar bone scans during Screening).
• History of visceral metastasis, or presence of visceral metastasis detected by screening imaging examinations (according to central review at screening).
• Other malignancy treated within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer).
• Imminent spinal cord compression based on clinical findings and / or magnetic resonance imaging (MRI). - Participants with history of spinal cord compression should have completely recovered.
• Active or symptomatic viral hepatitis
• Inability to tolerate any of the other imaging procedures in the study (ie, bone SPECT/CT and planar bone scans with a Tc 99m phosphonate radiotracer, DXA scan, radium-223 SPECT/CT scans).
• Any condition, which in the opinion of the investigator would preclude participation in this trial.
• Hypersensitivity to radium-223 dichloride.
• Blood transfusion or erythropoietin stimulating agents 4 weeks prior to start of Screening and during the whole Screening period before enrollment into the cohort.
• Prior administration of an investigational therapeutic for CRPC.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patients with Low extent of disease; Adult men with bone mCRPC having < 6 bone metastases	Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
Experimental: Patients with High extent of disease; Adult men with bone mCRPC having ≥ 6 bone metastases	Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC of radium-223 in tumor-free bone after 3 doses	The uptake of radium-223 in bone is determined with single-photon emission tomography / computed tomography (SPECT/CT).	At 4, 24 and 144 hours post injection at Cycle 3 ( total duration of one cycle is 28 days).

Secondary Outcome Measures

Outcome Measure	Time Frame
AUC of radium-223 in tumor-free bone after single dose	At 4, 24 and 144 hours post injection at Cycle 1 ( total duration of one cycle is 28 days).
AUC of radium-223 in tumor-free bone after 6 doses	At 4, 24 and 144 hours post injection at Cycle 6 ( total duration of one cycle is 28 days).

Collaborators and Investigators

• Sponsor: Bayer

Publications and helpful links

Helpful Links

• Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.

Study record dates

Study Major Dates

• Study Start (Actual): November 16, 2020
• Primary Completion (Actual): October 10, 2023
• Study Completion (Actual): August 27, 2025

Study Registration Dates

• First Submitted: August 3, 2020
• First Submitted That Met QC Criteria: August 18, 2020
• First Posted (Actual): August 20, 2020

Study Record Updates

• Last Update Posted (Estimated): September 19, 2025
• Last Update Submitted That Met QC Criteria: September 18, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: phase I; Metastatic castration-resistant prostate cancer (mCRPC); Single-photon emission tomography / computed tomography (SPECT/CT); radium-223,
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms; Antineoplastic Agents; radium Ra 223 dichloride
• Other Study ID Numbers: 20511; 2019-000475-17 (EudraCT Number); 2023-506435-15-00 (Registry Identifier: CTIS(EU))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

IPD Plan Description

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No